NEW

Activ Surgical Announces FDA Clearance for ActivSight Intraoperative Imaging Module

Activ Surgical announced the U.S. Food and Drug Administration (FDA) 510(k) clearance of the company’s ActivSight Intraoperative Imaging Module for enhanced surgical visualization.

Metrex Surface Disinfectant Portfolio Secures EPA Approval

The U.S. Environmental Protection Agency (EPA) has approved all eight surface disinfectant products made by an infection prevention leader, Metrex, as effective against SARS-CoV-2, the novel coronavirus that causes COVID-19.

Olympus Supports Safety Actions Regarding Surgical Smoke

Olympus has announced its support of The Joint Commission’s recommended safety actions for managing the hazards of exposure to surgical smoke for health care staff in operating rooms.

Exofin Fusion Redesign Receives FDA Approval

Chemence Medical, a leader in medical cyanoacrylate devices and products, announced the U.S. Federal Drug Administration’s (FDA) 510(k) approval of the company’s redesigned exofin fusion skin closure system.

ValueHealth Announces Joint Venture with Capital Health

ValueHealth LLC, a tech-enabled surgical platform company, has announced a new joint venture with New Jersey-based health system Capital Health. This strategic partnership will expand ValueHealth’s market share in the Mid-Atlantic region and position the company for further growth opportunities.

Rendering of Bordentown Surgery Center

“This partnership helps solidify our efforts to provide full market coverage to the larger Philadelphia and New Jersey regions,” said ValueHealth Chairman John R. Palumbo. “We look for partners who are aligned with our commitment to deliver value-based care with the country’s highest clinical outcomes and unprecedented patient experience while lowering costs for employers and patients. Capital Health is a partner that is aligned clinically, economically, and strategically to serve its community.”

“Board and executive teams are tasked with balancing competing capital priorities: inpatient, outpatient, infrastructure, revenue generation, and new markets core business,” said Capital Health President and CEO Al Maghazehe, PhD, FACHE. “With this expansion, Capital Health’s long-range planning and strategy to broaden our reach into surrounding markets, bringing total joint replacements and other high-acuity procedures to a state-of-the-art outpatient setting, will propel us forward as a health system of the future.”

The new Bordentown surgery center will be designated through ValueHealth’s nationally recognized Ambulatory Centers of Excellence (ACE)™ program with an Advanced Total Joint Certification, meaning it will not only exceed national accrediting standards, but it will also meet ValueHealth’s stricter clinical, quality, and financial measures. The 23,000 square foot ASC will deliver hyperspecialized, high-value surgical procedures, including total joint replacement, in a state-of-the-art facility featuring four operating rooms and six recovery StaySuites™ that use a proven recovery model to reduce risks for patient readmission and post-operative complications. ValueHealth’s digital surgical platform, which includes patient steerage, payor bundles, and warranty contracts, will empower the facility to handle approximately 6,000 cases per year.
The facility will serve the needs of Capital Health and the surrounding community, including a growing network of over 400 employed physicians. The estimated occupancy date is Q1 2021.

“Health systems are faced with capacity challenges, especially during this current pandemic, driving uncertainty,” said Palumbo. “Our industry will recover, and when we do, volumes will be significant. Having a clear, future-forward strategy to capture case volume and market growth to safe, high-tech facilities is now more important than ever. We are proud to bring this opportunity to the surrounding communities we serve.”

Previous

Next

Submit a Comment

Your email address will not be published. Required fields are marked *

X